This year’s CPHI conference in Europe will introduce a new sustainability summit, as well as exhibitor zones focusing on AI, contamination control and logistics. CPHI...

Novo Nordiskhas announced headline results from the cardiovascular outcomes from a phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway,...

Kodiak Sciences Inc. has completed enrolment of the first 300-patient cohort in its clinical trial, supporting pivotal analysis of the KSI-101 phase 3 programme...